Biocon

Biocon Biologics at Chennai is a 56000 sq. ft RND centre equipped with end-to-end cutting-edge infrastructure involving upstream, downstream, formulation, analytical characterization, functional characterization, and pilot facilities. A world-class team is being put together to develop biosimilar therapies all the way through process development, characterization, scale-up, and technology transfer to feed into our large-scale manufacturing facilities at Bangalore.

HIRING for Quality Department

Biocon Biologics at Chennai is a 56000 sq. ft RND centre equipped with end-to-end cutting-edge infrastructure involving upstream, downstream, formulation, analytical characterization, functional characterization, and pilot facilities. A world-class team is being put together to develop biosimilar therapies all the way through process development, characterization, scale-up, and technology transfer to feed into our large-scale manufacturing facilities at Bangalore. We are looking for passionate science-driven minds at all levels across different functions.

Biocon Biologics at Chennai is a 56000 sq. ft RND centre equipped with end-to-end cutting-edge infrastructure involving upstream, downstream, formulation, analytical characterization, functional characterization, and pilot facilities. A world-class team is being put together to develop biosimilar therapies all the way through process development, characterization, scale-up, and technology transfer to feed into our large-scale manufacturing facilities at Bangalore. We are looking for passionate science-driven minds at all levels across different functions.

Biocon Biologics at Chennai is a 56000 sq. ft RND centre equipped with end-to-end cutting-edge infrastructure involving upstream, downstream, formulation, analytical characterization, functional characterization, and pilot facilities. A world-class team is being put together to develop biosimilar therapies all the way through process development, characterization, scale-up, and technology transfer to feed into our large-scale manufacturing facilities at Bangalore.

Biocon is global biopharmaceutical company changing patients lives in over 120 countries by finding new and affordable ways to treat diabetes, cancer and autoimmune diseases. Powered by advanced therapy platforms, our 12,000 plus employees blend heart, science and creativity to make better healthcare solutions. Biocons 4 global businesses include generics, biosimilars, research services and novel biologics. They represent Biocon’s risk-balanced strategy, underpinned by agile network connections, a robust pipeline and a timely emerging markets orientation.

Biocon is global biopharmaceutical company changing patients' lives in over 120 countries by finding new and affordable ways to treat diabetes, cancer and autoimmune diseases. Biocon is a research-driven, global healthcare company with a strong matrix of capabilities along the biopharmaceutical value chain.

Post : Executive

Biocon is global biopharmaceutical company changing patients lives in over 120 countries by finding new and affordable ways to treat diabetes, cancer and autoimmune diseases. Powered by advanced therapy platforms, our 12,000 plus employees blend heart, science and creativity to make better healthcare solutions. Biocons 4 global businesses include generics, biosimilars, research services and novel biologics. They represent Biocon’s risk-balanced strategy, underpinned by agile network connections, a robust pipeline and a timely emerging markets orientation.

Biocon is global biopharmaceutical company changing patients lives in over 120 countries by finding new and affordable ways to treat diabetes, cancer and autoimmune diseases. Powered by advanced therapy platforms, our 12,000 plus employees blend heart, science and creativity to make better healthcare solutions. Biocons 4 global businesses include generics, biosimilars, research services and novel biologics. They represent Biocon’s risk-balanced strategy, underpinned by agile network connections, a robust pipeline and a timely emerging markets orientation.